Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Acrux ( (AU:ACR) ) just unveiled an announcement.
Acrux Limited reported a significant increase in its September quarterly profit share income, surpassing the total income of the previous financial year. This growth is attributed to the successful market penetration of its recently launched products, including Nitroglycerin Ointment and Dapsone Gel, which have achieved substantial market shares. The company also received a $3.04 million R&D Tax Incentive Rebate from the Australian Tax Office, which facilitated the repayment of short-term advances from Radium Capital. Acrux’s strategic focus on expanding its portfolio of generic products and exploring international markets is expected to drive further revenue growth and enhance its industry positioning.
More about Acrux
Acrux Limited is a specialty pharmaceutical company based in Melbourne, Australia, focusing on the development, registration, manufacturing, and marketing of topical generic drugs. The company has a strong presence in the U.S. market with FDA-approved products and is exploring opportunities to expand its commercial reach internationally.
Average Trading Volume: 458,783
Technical Sentiment Signal: Sell
Current Market Cap: A$5.73M
See more insights into ACR stock on TipRanks’ Stock Analysis page.